Department of Pathology, Wroclaw Medical University, K. Marcinkowskiego 1, 50-368 Wrocław, Poland.
Department of Neurology, Regional Specialist Hospital, Koszarowa 5, 51-149 Wrocław, Poland.
Neurol Neurochir Pol. 2021;55(3):269-280. doi: 10.5603/PJNNS.a2021.0024. Epub 2021 Mar 12.
Glioblastoma is the most common, and the most lethal, primary malignant brain tumour in adults. The aim of the study was to present a comprehensive, data-based review of glioblastoma treatment research, considering all clinical trials and peer-reviewed journal publications.
Data regarding all glioblastoma clinical trials that was available on 7 August 2019 on ClinicalTrials.gov was analysed. Information on interventions' mechanisms of action was obtained from AdisInsight. A PubMed search for 'glioblastoma' was performed in September 2019. Citation counts were gathered from Scopus. Custom software for obtaining and analyzing data was developed by the authors.
1,388 clinical trials on glioblastoma with a start date between 1979 and 2020 were identified. The distribution of glioblastoma clinical trial phases differs significantly from that of other high-mortality cancers. 526 unique interventions of clinical trials and 206 molecular targets have been isolated. 32,410 publications on glioblastoma have been found, the number having increased especially since 2006. Publications on identified treatment options comprised 32.2%. Publications on glioblastoma are cited on average 4.27 times per year. The average specificity of treatment options' publications for glioblastoma is 6.9%.
Glioblastoma treatment options and their molecular targets can be quantitatively ranked according to their scientific research output. To the best of our knowledge, no such registries have been elaborated before.
胶质母细胞瘤是成人中最常见、也是最致命的原发性恶性脑肿瘤。本研究旨在对胶质母细胞瘤治疗研究进行全面、基于数据的回顾，考虑所有临床试验和同行评议的期刊出版物。
分析了 2019 年 8 月 7 日 ClinicalTrials.gov 上所有胶质母细胞瘤临床试验的数据。干预措施作用机制的信息是从 AdisInsight 获得的。2019 年 9 月在 PubMed 上对“glioblastoma”进行了检索。引文计数是从 Scopus 收集的。作者开发了用于获取和分析数据的定制软件。
共确定了 1388 项始于 1979 年至 2020 年的胶质母细胞瘤临床试验。胶质母细胞瘤临床试验的分期分布与其他高死亡率癌症显著不同。已分离出 526 种临床试验和 206 个分子靶点的独特干预措施。共发现 32410 篇胶质母细胞瘤的出版物，自 2006 年以来数量明显增加。确定的治疗方案出版物占 32.2%。关于胶质母细胞瘤的出版物平均每年被引用 4.27 次。治疗方案出版物对胶质母细胞瘤的平均特异性为 6.9%。
可以根据其科学研究产出对胶质母细胞瘤的治疗选择及其分子靶点进行定量排名。据我们所知，以前没有制定过这样的登记册。
